Rick Simpson Oil (RSO) in Baker County, Georgia: The Complete Guide by OilWell Cannabis

If you’re reading this in Baker County—maybe in Newton, Elmodel, or out in the quiet stretches of southwest Georgia—you’ve probably heard whispers about Rick Simpson Oil. Maybe a neighbor mentioned it for their arthritis. Maybe a family member across the state line in Florida or Alabama asked about it. Maybe you’re dealing with chronic pain from years of farm work, or helping a loved one through cancer treatment at Phoebe Putney in Albany, and you’re searching for options that the local clinic doesn’t talk about.

We get it. Baker County is rural. You’ve got the Dougherty County line to your east, Miller County to your south, and the closest dispensary might be a two-hour drive away—if you can even get a medical card. That distance is exactly why we wrote this guide. We believe every person in Baker County deserves access to honest, science-based cannabis education—not the hype, not the fear-mongering, but the real story about what RSO is, what it can and cannot do, and how our modern formulas address the safety and consistency problems that made the original Rick Simpson Oil a risky gamble.

OilWell Cannabis is a Houston-based cannabinoid company, but our mission extends to every underserved community in America, including Baker County. We’ve shipped our RSO to patients in rural Georgia, talked with veterans in Mitchell County, and helped folks in Calhoun County understand the legal landscape. This guide is for you.

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional. He was a power engineer and maintenance worker—a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine could not adequately resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials.

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed.

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement.

The crusade—spreading the oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. Operating out of his property in Maccan, Nova Scotia, he began making the oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era. Within cannabis communities, it was foundational—for many people, Run From The Cure was their introduction to the concept of concentrated cannabis oil as medicine.

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support and public attention, he was raided again in 2009. He was acquitted on some charges but convicted on others. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, a book detailing his personal experience, his oil-making process, and his broader philosophical views on cannabis, medicine, and institutional suppression. He also maintained phoenixtears.ca as his primary online platform for information and advocacy.

Throughout his public career, Simpson’s position remained consistent and uncompromising: he maintained that cannabis oil—particularly high-THC oil made according to his specific method—could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect their financial interests. He framed his work not merely as health advocacy but as a fight against institutional corruption.

Important context: Simpson’s conspiratorial framing is noted here without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding why RSO became culturally significant.

The traditional RSO protocol—Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over a period of roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions.

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times per day (morning, afternoon, and before bed). Total daily intake during this phase: approximately 30 to 45 milligrams.
• Weeks 2 through 5: Double the dose approximately every four days. The target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.
• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed.

Administration methods

• Primary method—oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it.
• Secondary method—topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days.
• Not recommended as primary—inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method, though he acknowledged inhalation for immediate symptom relief.

Tolerance and the psychoactive effects

• Simpson maintained that patients would develop significant tolerance to the psychoactive effects of THC within approximately three to four weeks of consistent dosing at escalating levels.
• He considered the euphoric, sedating, or disorienting effects a minor and temporary side effect and strongly urged patients not to let the high discourage them from continuing the protocol.
• He recommended that patients take their initial doses at night or before bed to sleep through the most intense psychoactive effects during the early titration phase.
• Simpson also recommended that patients avoid driving or operating machinery during the titration period and that they inform family members about what to expect.

Post-protocol maintenance

After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.

Dietary and lifestyle recommendations

Simpson also advocated for dietary changes alongside the oil protocol, including reducing sugar intake, avoiding processed foods, and improving overall nutrition, though he was not specific or systematic about dietary protocols compared to his highly detailed oil protocol.

Important context for evaluating this protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or even well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or any other condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely.
• Very high THC exposure. At the peak dosing phase, patients were consuming roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder.
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment—potentially in place of proven therapies—introduces harm that extends beyond the oil itself.

What is traditional Rick Simpson Oil—the product

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials.

Source material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization—the starting material varied by availability and growing season.

Extraction solvent

Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which is a significant safety issue.

Extraction process

1. Dry or semi-dry cannabis plant material was placed in a container (typically a bucket).
2. The material was covered with solvent and agitated or stirred for several minutes.
3. The solvent was poured off through a filter into a separate collection vessel.
4. The process was repeated a second time with fresh solvent.
5. The combined solvent washes were placed in a rice cooker or similar open-vessel heating device.
6. The solvent was evaporated at relatively low heat.
7. As the solvent evaporated, a thick, dark oil remained at the bottom of the vessel.
8. The final oil was transferred into oral syringes for storage and dosing.

Appearance and physical characteristics

Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on how thoroughly the solvent was purged. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC. The heat involved in solvent evaporation converted essentially all THCa into delta-9 THC.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.
• No ratio control. There was no ability to adjust or standardize specific cannabinoid ratios.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight.

Terpene content

Minimal to none. The combination of solvent extraction and high-heat evaporation meant that traditional RSO was effectively stripped of its terpene content.

Standardization and testing

None. Every batch of traditional RSO was different because it depended entirely on the starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process.

Residual solvent risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging leaves potentially harmful residues in the finished oil.

Simpson’s claims vs. the evidence record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer—including terminal cases—and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions.

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally.

What the preclinical literature shows

The preclinical cannabinoid-cancer literature does exist, and it is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines.
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids.
• These findings have generated legitimate scientific interest and ongoing research.

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts have been conducted, but they have been exploratory and have not produced results that would support cancer-cure claims.

Institutional positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment.
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer.
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not cancer cure.

What Simpson got right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy—however scientifically imprecise—helped create the political, cultural, and social conditions for the legal cannabis industry. He was among the first to bring concentrated cannabis oil to widespread public awareness.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies carries genuine harm potential.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly—and often loosely—across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format.

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent. Simpson’s model was explicitly anti-commercial—he gave the oil away for free and urged others to make their own rather than buy from companies.

This philosophical tension is worth acknowledging. Whether the evolution from DIY free distribution to commercial standardized products represents improvement or betrayal depends on one’s perspective.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes solve real problems that limited Simpson’s original vision.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew. OilWell’s formulas intentionally include seven cannabinoids because the entourage-effect literature suggests potential benefit from cannabinoid diversity.
• Terpene preservation and addition. Traditional RSO had essentially no terpene content. OilWell includes live terpenes at 5 percent with a specific seven-terpene profile.
• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor.
• Reduced delta-9 THC dominance. Traditional RSO was 60 to 90 percent delta-9 THC. OilWell’s formula uses delta-9 THC at only 90 mg while distributing the remaining cannabinoid content across CBD, CBG, delta-8 THC, CBN, and CBC.
• Product format innovation. Simpson envisioned only one format: an oral oil. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation.

Solvent safety and extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither of which is food-grade. Naphtha may contain benzene, toluene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging leaves potentially harmful residues.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods.

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha, no isopropyl alcohol, no butane. The product uses organic MCT oil as the carrier base.

The decarboxylation question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent converted essentially all THCa into delta-9 THC. As a result, the acidic cannabinoids that exist abundantly in raw cannabis were lost.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This creates three distinct usage options:

Option 1—Raw, no heat. All 1,500 mg stays as THCa—completely non-psychoactive. Compatible with work, driving, and daytime use with zero impairment.

Option 2—Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45 to 60 minutes converts 1,500 mg of THCa into approximately 1,315 mg of delta-9 THC. Combined with the existing 90 mg of delta-9 THC, this yields approximately 1,405 mg of total delta-9 THC—the same psychoactive potency as traditional high-THC RSO, entirely at the customer’s discretion.

Option 3—Vape, auto-decarboxylation. The vape cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation.

Terpene loss in traditional RSO

Traditional RSO was essentially stripped of terpenes by the solvent and heat process. OilWell’s formulas specify live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene.

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. His evidence was anecdotal. His production was unstandardized. His claims were untested.

OilWell takes a fundamentally different approach. This document applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around crude, single-strain extract. A direct comparison between his dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward.

Several key differences illustrate why:

• Cannabinoid concentration: OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios: Simpson’s oil was approximately 60 to 90 percent delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across multiple compounds.
• Terpene presence: Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5 percent.
• Delta-9 THC exposure: Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle.

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by the per-compound evidence and by responsible titration principles.

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. Colin’s childhood was marked by exposure to violence, with best friends killed or imprisoned. By sixteen, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths. He focused on cannabis, seeing it as a safer alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines OilWell’s approach.

Bentley’s story—the real beginning

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet—he was family. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs.

But giving up on Bentley was not an option. In a desperate search for alternatives, Colin stumbled upon CBD through a question that changed everything. A rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline. And that lifeline delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect—dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Colin’s personal battle—PTSD and benzo addiction

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat notoriously difficult and dangerous—using the cannabinoid knowledge he developed keeping Bentley alive.

The Peace Gummies formula was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

From Houston to Baker County—our reach

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 KTRK Houston—Houston’s number-one news source—featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city. That same expertise is now available to Baker County residents through this guide and through our direct shipping.

Colin’s quote from the first ABC13 feature in September 2019 captures the OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed. But we don’t just serve Houston—we serve every community that mainstream cannabis has left behind, including Baker County.

The OilWell RSO philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define OilWell’s approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across the United States and internationally to customers who verify local legality. For Baker County residents, this means no drive to Albany, no waiting for a medical appointment, no qualifying condition needed. If you’re in Newton or anywhere in Baker County, you can order directly and have it delivered to your door.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. For Baker County residents who work in agriculture, drive farm equipment, or need to stay functional during the day, the raw option provides therapeutic benefit without impairment. For those needing maximum relief at night, activation is simple.

3. Open-source formulas. OilWell publishes complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. In a rural county like Baker, where economic resources may be limited, this philosophy matters. We’re not just selling a product; we’re sharing knowledge.

4. Evidence-informed, not evidence-overstating. This entire document represents OilWell’s commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature; OilWell has that access and uses it to distinguish between what is well-supported, what is emerging, and what is overstated. Baker County residents deserve the same standards as Houston medical professionals.

Farm Bill compliance and the THCa legal framework for Baker County, Georgia

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level. This framework is the foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—well under the 0.3 percent threshold. All cannabinoids are hemp-derived. The product is legal under federal law and in Georgia.

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. It is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams, this produces approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at the customer’s discretion.

This means the same product can function as a non-psychoactive anti-inflammatory or as a full-potency psychoactive cannabinoid product. For Baker County residents dealing with chronic pain during the day, raw THCa offers relief without impairment. For nighttime cancer support, activation provides the potency Simpson advocated.

Important legal notice for Baker County residents: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with local laws. Georgia law permits hemp-derived products with less than 0.3% delta-9 THC. OilWell ships with full documentation, Certificates of Analysis, and receipts. We have successfully delivered to rural Georgia counties; customs and legal responsibility rests with the customer.

Open-source formulas—why we publish everything for Baker County

We publish complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. The formulas in the RSO Sublingual Oil and RSO Vape Cartridge sections of this document are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. OilWell adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

CBD golden paste recipe for pets—the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water. In a saucepan, combine the turmeric powder and water, stirring over low heat. Stir continuously until it forms a thick paste (7 to 10 minutes). Add a little more water if it becomes too thick.
2. Add the coconut oil and pepper. Once you have a thick paste, add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Cool and store. Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Dosage. Add a small amount of CBD oil to the paste before giving it to the pet.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. This is the formula that saved Bentley—the formula that started everything.

The decarboxylation choice—patient-controlled potency for Baker County lifestyles

Traditional RSO was always fully decarboxylated, leaving the patient with no choice about psychoactivity. OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form, creating three distinct usage options:

Option 1—Raw, no heat (Daytime functional use for Baker County workers). All 1,500 mg stays as THCa—completely non-psychoactive. Compatible with operating farm equipment, driving to Albany for appointments, or working at the Baker County courthouse with zero impairment.

Option 2—Fully activated, home decarboxylation (Nighttime therapeutic use). Heating converts THCa to approximately 1,315 mg of delta-9 THC. Combined with existing delta-9 THC and delta-8 THC, this achieves potency comparable to traditional high-THC RSO.

Option 3—Vape, auto-decarboxylation (Fast relief for acute symptoms). Every puff delivers freshly decarboxylated cannabinoids within 1-2 minutes—ideal for breakthrough pain or panic.

The conversion chemistry: 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule.

Solvent-free production

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios. No naphtha, no isopropyl alcohol, no butane. The product uses organic MCT oil as the carrier base.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production—a critical consideration for Baker County residents who may have encountered poorly made homemade products.

Third-party lab testing covers cannabinoid potency, terpene profile, pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request.

The broader OilWell product portfolio

Beyond RSO, OilWell produces:

• Asshole Peach—OilWell’s most popular product, particularly favored by veterans for PTSD and pain relief.
• Peace Gummies—developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. The formula is also available in vape form.
• Custom creations—OilWell offers custom-made products tailored to specific cannabinoid ratios, delivery formats, or unique health circumstances, including formulations for vegans and diabetics.

Two product formats for Baker County needs

RSO Sublingual Oil—$129.99

• 30 mL bottle
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes
• Duration: 4 to 6 hours
• Approximately 40 to 60 doses per bottle

RSO Vape Cartridge—$49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest delivery)
• Duration: 2 to 4 hours
• Automatic THCa decarboxylation at vaping temperature

When to use each format in Baker County

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset—crucial for breakthrough symptoms
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration—ideal for overnight relief
Maximum bioavailability	Sublingual	13-19% absorption for stronger effect per mg
Portability (working fields, traveling)	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper for accuracy
Daytime non-psychoactive use	Sublingual (raw)	Zero impairment for farm work or driving
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Full potency for severe conditions

Competitive comparison—why Baker County residents choose OilWell

OilWell RSO vs. Texas TCUP dispensary RSO (e.g., Texas Original)

Dimension	TCUP dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (approx. 420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
Patient-controlled potency	No—always fully psychoactive	Yes—THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Delivery to Baker County	Must travel to physical dispensary	Direct shipping to your door in Baker County
Farm Bill compliant	No—state medical cannabis program	Yes—less than 0.3% delta-9 THC

OilWell RSO vs. hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	Approximately 950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
Psychoactive option	No meaningful psychoactive effect	Yes—via THCa decarboxylation and delta-8 THC
Price	$40 to $50	$129.99 (more potent per dollar)

Condition-specific usage context for Baker County

Important disclaimer: These are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. Always consult a qualified healthcare provider before using cannabinoid products. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support (for patients traveling to Albany’s cancer centers)

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief
• Post-chemo: 0.5 mL sublingual every 6 hours as needed

Chronic pain (common in agricultural work, arthritis, back injuries)

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory effect without psychoactive impairment for field work
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Sleep support

• Before bed: 1.0 to 2.0 mL sublingual delivers 25-50 mg CBN—the dosage level investigated in 2024 sleep literature

Anxiety and stress

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety without impairment

General titration principle for Baker County users: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, and concurrent medications.

Delivery and global accessibility to Baker County, Georgia

OilWell operates the only same-day RSO delivery system in Houston. For Baker County, we offer nationwide shipping that reaches your rural address—something no local dispensary can match.

Nationwide shipping to Baker County

• All Georgia counties where Farm Bill-compliant products are legal (including Baker County)
• USPS Priority Mail (2 to 3 business days), FedEx and UPS Ground (3 to 5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for Georgia summers
• Signature-required option available

International shipping

OilWell ships internationally and has delivered to multiple countries. Because the product contains less than 0.3% delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

• All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes
• Customers are responsible for verifying legality in their jurisdiction

For Baker County residents, this means no need to drive to Albany, Dougherty County, or across state lines. The product comes directly to you, legally, with full documentation.

How the OilWell formulas connect to the evidence in this document

Every cannabinoid in OilWell’s formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in the GENERAL KNOWLEDGE section of this document. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

The formulas published in this document are not standalone product listings. They are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging, and what is overstated.

OilWell holds itself to the same evidence standards applied to the broader cannabinoid field. That is intentional. As Colin Valencia said in 2019, people deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it is right or wrong for them.

OilWell Cannabis is more than a brand—it is a promise to our customers that we will always strive to deliver the best, most thoughtful cannabis products available. And as we continue to grow, our focus remains on maintaining the same level of integrity, creativity, and commitment that defined us from the day Bentley got up, walked across the room, and brought his ball to play.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia—Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston (KTRK) featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter.

Feature: Texas CBD businesses booming as industry continues to evolve—September 15, 2019

Reporter: Tom Abrahams
Published: Sunday, September 15, 2019

Colin’s foundational quote: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This quote— from 2019, years before the formulas were published—is the seed of everything OilWell would become.

Feature: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts—March 22, 2021

Reporter: Tom Abrahams
Published: Monday, March 22, 2021

Colin’s therapy quote: “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

Feature: What is Delta 8 THC and why is it considered legal weed in Texas—May 24, 2021

Reporter: Steve Campion
Published: Monday, May 24, 2021

Colin’s iconic exchange:
Steve Campion: “Why would someone want to smoke that?”
Colin Valencia: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

This investigative feature became one of the most widely referenced ABC13 cannabis segments.

Feature: Houston CBD shop giving away free products to those who get COVID vaccine—August 20, 2021

Reporter: KTRK Staff
Published: Friday, August 20, 2021

OilWell gave away approximately $35,000 in product (1,000 caviar pre-rolls) to encourage COVID-19 vaccination. The giveaway was hosted at HydroShack Hydroponics in The Heights. OilWell coordinated with the city of Houston to amplify vaccination efforts.

OilWell’s Instagram post: “We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”

Feature: Texas ban over once legal hemp product Delta 8 raises questions over legality—October 19, 2021

Reporter: Shelley Childers
Published: Tuesday, October 19, 2021

When Texas DSHS classified Delta-8 as Schedule I overnight, Colin proactively removed all Delta-8 products before enforcement began and warned other operators who were unknowingly shipping Schedule I narcotics.

Colin: “It’s going to be a surprise to a lot of people.”
“So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”
“It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.”

Texas DSHS told ABC13 that Delta-8 “has always been illegal” but could not explain how the market had been “allowed to publicly blossom and thrive while being considered illegal.”

Feature: Biden marijuana pardon—experts weigh in on why Texas won’t see impact—October 7, 2022

Reporter: Nick Natario
Published: Friday, October 7, 2022

This feature revealed Colin’s personal marijuana conviction history, transforming the entire media record.

Colin: “You face challenges with housing, loans, and banking, I mean with about everything.”
“I would love to see people not get hurt for this anymore.”

Feature: Marijuana industry getting creative as Texas laws continue to change—April 21, 2023

Reporter: Nick Natario
Published: Friday, April 21, 2023

Colin’s “Renaissance” framing: “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

The feature noted that Texas has around 10,000 active medical marijuana patients, compared to Florida’s 700,000 despite having two-thirds the population.

The through-line—what the media record reveals

Taken together, these seven ABC13 features tell a story that no single article could capture:

• Consistency across years—from 2019 to 2023, ABC13 returned to Colin as a primary source
• Breadth of expertise—business, law, medicine, community health, politics
• Community action—$35,000 vaccine giveaway, proactive Delta-8 removal
• Personal stakes—Colin’s cannabis conviction history revealed
• Evolution of language—from “local wholesaler” to industry authority

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible voice in Houston’s legal cannabis industry. That recognition cannot be purchased—it can only be earned.

GENERAL KNOWLEDGE

Research method and evidence weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. The evidence base is not evenly distributed. CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, and in vitro pharmacology.

Institutional baseline from NIH and related sources

• NCCIH states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS.
• The FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals.
• Safety concerns include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, contamination, labeling inaccuracy, and THC-vape lung-injury concerns.

Cannabinoids

CBD

• Evidence profile: strongest human evidence, especially for seizure disorders
• Anxiety research: 2024 systematic review found statistically significant anxiolytic signal but stressed limited clinical sample
• Pain research: 2024 systematic review concluded promising but heterogeneous evidence
• Sleep research: 2023 insomnia review found methodologically weak literature
• Safety: 2023 systematic review found real signal for liver enzyme elevation and possible drug-induced liver injury
• Bottom line: most evidence-developed nonintoxicating cannabinoid, but strong evidence concentrated in specific indications

CBG

• Evidence profile: mostly review-level and preclinical; human evidence remains sparse
• Pharmacology: distinct from THC and CBD; interactions with cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A signaling
• Bottom line: promising minor cannabinoid with limited clinical validation

Delta-8 THC

• Evidence profile: pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC
• Comparative pharmacology: 2022 review concluded broadly similar pharmacokinetic and pharmacodynamic behavior to delta-9 THC, but less potent
• Public-health literature: 2023 scoping review found evidence base dominated by animal studies and public-health concerns
• Bottom line: psychoactive THC analogue with real pharmacologic activity and incomplete human safety characterization

THCa

• Evidence profile: important chemically and formulation-wise, but low on direct human therapeutic evidence
• Psychoactivity: does not produce psychoactive effects associated with THC, but heating converts it to THC
• Research status: in vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities
• Bottom line: highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage

Delta-9 THC

• Evidence profile: strongest human evidence of psychoactive cannabinoids, but clearest adverse-effect burden
• Institutionally best supported: chemotherapy-related nausea, appetite/weight loss in HIV/AIDS, some MS and pain outcomes
• Pain evidence: 2022 systematic review found high THC products may provide short-term pain benefit but increase dizziness, sedation, nausea
• Pharmacokinetics: inhaled onset within seconds to minutes; oral onset later, peak later, duration longer
• Mental-health risk: 2025 systematic review found consistent unfavorable associations with psychosis/schizophrenia and cannabis use disorder
• Bottom line: legitimate therapeutic relevance but carries clearest intoxication, psychiatric, and dose-related safety liabilities

CBN

• Evidence profile: weak human evidence; marketing has moved ahead of data
• Sleep research: 2021 narrative review screened 99 human-study abstracts and found no clinical trials using validated sleep questionnaires or polysomnography
• Bottom line: clearest example where cultural reputation is stronger than clinical evidence

CBC

• Evidence profile: emerging, intriguing, overwhelmingly preclinical or review-based
• Pharmacology: distinct pharmacodynamics, pharmacokinetics, and receptor behavior
• Research themes: antinociceptive, antibacterial, anti-seizure areas
• Bottom line: scientifically credible minor cannabinoid deserving more research

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models. Robust proof of clinically meaningful entourage effects in humans remains limited.

Limonene

• Evidence profile: largely review and preclinical
• Potential activity: antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory
• Safety note: oxidation products are clinically relevant contact allergens
• Bottom line: biologically active but cannabis-specific therapeutic claims should stay conservative

Myrcene

• Evidence profile: mostly preclinical, very limited human evidence
• Research summary: anxiolytic, antioxidant, anti-inflammatory, analgesic properties described
• Bottom line: plausible bioactive terpene but compound-specific clinical claims remain ahead of proof

Caryophyllene

• Evidence profile: among most mechanistically interesting due to CB2 receptor agonism
• Standout feature: selective CB2 receptor agonist, unusual for a terpene
• Bottom line: strongest candidate for cannabinoid-system significance but not clinically proven

Pinene

• Evidence profile: promising preclinical literature, weak human confirmation
• Brain-health framing: antioxidant, anti-inflammatory, neuroprotective signals justify future study
• Bottom line: deserves scientific attention but strong cognition claims are exploratory

Linalool

• Evidence profile: substantial preclinical interest, limited direct clinical confirmation
• Safety note: oxidized linalool hydroperoxides are recognized allergens
• Bottom line: scientifically credible but current evidence supports cautious phrasing

Humulene

• Evidence profile: translationally interesting but still early
• Scoping-review findings: broad preclinical evidence for anti-inflammatory effects
• Bottom line: interesting research target but far from clinically settled

Terpinolene

• Evidence profile: one of least clinically characterized
• Systematic-review findings: evidence base dominated by in silico, in vitro, and animal studies
• Bottom line: biologically interesting but especially underdeveloped clinically

Research limits and interpretation

• The evidence base is highly uneven. CBD and delta-9 THC support the most detailed statements; others require more caution.
• Extract/molecule/synthetic/terpene data are not interchangeable.
• Minor cannabinoids and terpenes are commercially interesting because they are underexplored, but claims often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, and dose variability all affect interpretation.
• For THCa, chemistry is destiny: storage and heating can change exposure profile.

Common overstatements to avoid

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: specific sleep evidence for CBN remains weak, with no strong validated-trial base.
• Overstatement: myrcene is a proven human sedative.
  More accurate: myrcene has plausible preclinical bioactivity but direct human proof is limited.
• Overstatement: terpenes have proven entourage effects.
  More accurate: entourage hypotheses are influential but robust clinical proof remains limited.
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating can convert it to THC.
• Overstatement: delta-8 THC is safe because it is hemp-derived.
  More accurate: delta-8 THC is psychoactive with incomplete safety characterization.

Practical takeaways for the formulas in this document

• The most evidence-developed actives are CBD and delta-9 THC.
• Delta-8 THC is not trivial; it is a psychoactive cannabinoid with less robust safety data.
• THCa meaningfully changes with processing.
• CBG, CBN, and CBC are scientifically credible but clinically immature.
• Terpene claims should be careful and only where directly supported.

References

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH.
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy. Exp Neurol. 2023;359:114238.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders. Psychiatry Res. 2024;339:116049.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia. Cannabis Cannabinoid Res. 2023;8(2):213-229.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity. J Intern Med. 2023;293(6):724-752.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review. Molecules. 2024;29(22):5471.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC. Br J Pharmacol. 2022;179(15):3915-3933.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review. Addiction. 2023;118(6):1011-1028.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249.
12. Moreno-Sanz G. Can You Pass the Acid Test? Cannabis Cannabinoid Res. 2016;1(1):124-130.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain. Ann Intern Med. 2022;175(8):1143-1153.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes. Ann Intern Med. 2025;178(10):1429-1440.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep. Curr Psychiatry Rep. 2024;26(12):712-727.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products. Pharmaceuticals Basel. 2024;17(11):1543.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound. J Food Biochem. 2021;45(1):e13566.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review. Contact Dermatitis. 2022;87(1):1-12.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits? Front Nutr. 2021;8:699666.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties of beta-caryophyllene. Biomed Pharmacother. 2021;140:111639.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of pinene and linalool as terpene-based medicines for brain health. Front Psychiatry. 2021;12:583211.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic tool in depression treatment. Curr Neuropharmacol. 2022;20(6):1073-1092.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene. Planta Med. 2024;90(9):664-674.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene. Phytomedicine. 2021;93:153768.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364.

RSO SUBLINGUAL OIL FORMULA

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5%
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg

RSO VAPE CARTRIDGE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%
• Format: 1 Gram cartridge

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene—pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

HOW TO ORDER RSO IN BAKER COUNTY, GEORGIA

Baker County residents have three simple options:

1. Order online at OilWellCBD.com—select RSO Sublingual Oil or RSO Vape Cartridge, checkout, and we’ll ship directly to your Baker County address
2. Call us at (832) 416-2816—speak with our team about which product fits your needs and place your order by phone
3. Email us at [email protected]—ask questions, request COAs, or get personalized product guidance

All orders include:

• Full Certificate of Analysis (COA) for potency and safety
• Discreet, temperature-stable packaging
• Tracking information
• Customer support throughout your journey

For Baker County, Georgia, we typically ship via USPS Priority Mail, arriving in 2-3 business days. No need to drive to Albany, no need to cross state lines. Legal, lab-tested RSO delivered to your door.

Final words for Baker County: Whether you’re in Newton dealing with chronic pain from decades of physical work, or caring for a loved one in Elmodel, or simply exploring options that your local doctor hasn’t mentioned—we see you. We’ve built this product for people like you, in communities like yours. The science is real, the access is legal, and the option is yours.

We’re not here to sell you hope. We’re here to give you the best possible version of the information and the product, so you can decide what’s right for you. That’s the OilWell promise, from Houston to Baker County and everywhere in between.